JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

15.45 1.64

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.38

Max

15.56

Chiffres clés
By Trading Economics
Revenu	-2.2M -12M
Employés	37
EBITDA	-2.1M -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+104.4% upside

Dividendes
By Dow Jones
Prochains Résultats	7 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	7.7M 1.3B
Ouverture précédente	13.81
Clôture précédente	15.45

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

3.165 / 3.5827 Support & Résistance

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 mai 2026, 23:43 UTC

Principaux Événements d'Actualité

New Zealand's Unemployment Rate Falls in 1Q

5 mai 2026, 23:20 UTC

Actions en Tendance

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mai 2026, 21:48 UTC

Résultats

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mai 2026, 21:05 UTC

Acquisitions, Fusions, Rachats

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mai 2026, 22:08 UTC

Résultats

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mai 2026, 22:07 UTC

Résultats

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:48 UTC

Résultats

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mai 2026, 21:48 UTC

Résultats

Pan American Silver 1Q Rev $1.2B >PAAS

5 mai 2026, 21:42 UTC

Résultats

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:38 UTC

Résultats

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:30 UTC

Résultats

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:29 UTC

Résultats

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:26 UTC

Résultats

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mai 2026, 21:25 UTC

Résultats

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mai 2026, 21:25 UTC

Résultats

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mai 2026, 21:24 UTC

Résultats

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:18 UTC

Résultats

Mistras Backs 2026 Rev $730M-$750M >MG

5 mai 2026, 21:17 UTC

Résultats

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mai 2026, 21:15 UTC

Résultats

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mai 2026, 21:12 UTC

Résultats

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mai 2026, 21:11 UTC

Résultats

SSR Mining 1Q Rev $581.8M >SSRM

5 mai 2026, 21:10 UTC

Résultats

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mai 2026, 21:10 UTC

Résultats

SSR Mining 1Q EPS $1.16 >SSRM

5 mai 2026, 21:08 UTC

Résultats

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:01 UTC

Résultats

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mai 2026, 21:01 UTC

Actions en Tendance

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

104.4% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 104.4%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

3.165 / 3.5827Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.